Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

BeOne Medicines Ltd. - American Depositary Shares (NQ:ONC)

359.00 +10.73 (+3.08%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 10, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	833,362
Open	351.20
Bid (Size)	357.00 (80)
Ask (Size)	365.00 (40)
Prev. Close	348.27
Today's Range	349.90 - 361.33
52wk Range	253.95 - 385.22
Shares Outstanding	1,211,067,023
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration

Today 6:00 EDT

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines Q2 Earnings Call Highlights ↗

August 05, 2026

BeOne Medicines (NASDAQ:ONC) reported second-quarter revenue of $1.7 billion, up 30% from a year earlier, and GAAP earnings per ADS of $2.05, up 144%, as sales of its BTK inhibitor BRUKINSA continued...

Via MarketBeat

Performance

YTD	+15.4%	+15.4%
1 Month	+18.1%	+18.1%
3 Month	+15.5%	+15.5%
6 Month	+2.9%	+2.9%
1 Year	+23.9%	+23.9%

More News

BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates

August 05, 2026

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines

July 23, 2026

From BeOne Medicines Ltd.

Via Business Wire

A BeOne Founder Sold $34.6 Million in Stock but Keeps a Massive Position ↗

July 22, 2026

Via The Motley Fool

BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5

July 17, 2026

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma

June 30, 2026

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026

June 12, 2026

From BeOne Medicines Ltd.

Via Business Wire

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit

June 11, 2026

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3 ↗

June 02, 2026

Via MarketBeat

BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026

June 01, 2026

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026

May 29, 2026

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026

May 27, 2026

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

May 26, 2026

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts

May 21, 2026

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines Launches One Save Changes Everything, a Global Cancer Care Awareness Campaign with Soccer Legend Tim Howard

May 20, 2026

From BeOne Medicines Ltd.

Via Business Wire

Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares ↗

May 16, 2026

Via The Motley Fool

What to Know About This Fund’s $50 Million Exit From Ascendis Pharma ↗

May 14, 2026

Via The Motley Fool

This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO ↗

May 14, 2026

Via The Motley Fool

Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700% ↗

May 14, 2026

Via The Motley Fool

BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma

May 13, 2026

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates

May 06, 2026

From BeOne Medicines Ltd

Via Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA

April 29, 2026

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines to Announce First Quarter 2026 Financial Results on May 6

April 22, 2026

From BeOne Medicines Ltd.

Via Business Wire

This Fintech Stock Is Up 21% in a Year as Profits Surge, but One Fund's Nearly $300 Million Sale Cut Its Stake in Half ↗

March 19, 2026

Via The Motley Fool

Frequently Asked Questions

Is BeOne Medicines Ltd. - American Depositary Shares publicly traded?

Yes, BeOne Medicines Ltd. - American Depositary Shares is publicly traded.

What exchange does BeOne Medicines Ltd. - American Depositary Shares trade on?

BeOne Medicines Ltd. - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for BeOne Medicines Ltd. - American Depositary Shares?

The ticker symbol for BeOne Medicines Ltd. - American Depositary Shares is ONC on the Nasdaq Stock Market

What is the current price of BeOne Medicines Ltd. - American Depositary Shares?

The current price of BeOne Medicines Ltd. - American Depositary Shares is 359.00

When was BeOne Medicines Ltd. - American Depositary Shares last traded?

The last trade of BeOne Medicines Ltd. - American Depositary Shares was at 08/10/26 04:00 PM ET

What is the market capitalization of BeOne Medicines Ltd. - American Depositary Shares?

The market capitalization of BeOne Medicines Ltd. - American Depositary Shares is 434.77B

How many shares of BeOne Medicines Ltd. - American Depositary Shares are outstanding?

BeOne Medicines Ltd. - American Depositary Shares has 435B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.